PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins

(2019) Bozena Kaminska et al.   MOLECULES

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

(2019) Xu-Chao Zhang et al.   Nature Communications

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

(2019) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

760PPembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181

(2019) J Chen et al.   ANNALS OF ONCOLOGY

Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer

(2018) TUMENJIN ENKHBAT et al.   ANTICANCER RESEARCH

PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population

(2018) Kihwan Hwang et al.   JOURNAL OF NEURO-ONCOLOGY

Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma

(2018) Drew Pratt et al.   NEUROSURGERY

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas

(2018) Luyan Mu et al.   Frontiers in Molecular Neuroscience

PD-1 ( PDCD1 ) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase ( IDH ) Mutations

(2018) Lea Kristin Röver et al.   EBioMedicine

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma

(2018) Rimas V. Lukas et al.   JOURNAL OF NEURO-ONCOLOGY

Nobel committee honors tumor immunologists

(2018) Anand Rotte et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

(2018) Jiawen Qian et al.   Journal of Neuroinflammation

Integrated molecular characterization of IDH -mutant glioblastomas

(2018) A. Korshunov et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications

(2018) Kshama Gupta et al.   Frontiers in Oncology

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy

(2017) Song Xue et al.   Journal of Hematology & Oncology

Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome

(2017) Tsubasa Miyazaki et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma

(2017) Kyu Sang Lee et al.   JOURNAL OF NEURO-ONCOLOGY

Correlation of immune phenotype with IDH mutation in diffuse glioma

(2017) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Glioma Subclassifications and Their Clinical Significance

(2017) Ricky Chen et al.   Neurotherapeutics

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Comprehensive analysis of PD-L1 expression in glioblastoma multiforme

(2017) Dieter Henrik Heiland et al.   Oncotarget

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes

(2017) Qian Zhu et al.   OncoImmunology

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses

(2016) Leandro M. Colli et al.   CANCER RESEARCH

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies

(2016) Sarah T. Garber et al.   NEURO-ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

(2016) Jing Zeng et al.   Oncotarget

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

(2015) Elnaz Faghfuri et al.   Expert Review of Anticancer Therapy

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Glioblastoma multiforme: Pathogenesis and treatment

(2015) Constantinos Alifieris et al.   PHARMACOLOGY & THERAPEUTICS

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

(2015) Yi Qing et al.   Drug Design Development and Therapy

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells

(2015) Bo Yuan Huang et al.   PLoS One

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege

(2014) P. E. Fecci et al.   CLINICAL CANCER RESEARCH

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas

(2014) S. A. M. van Lith et al.   NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients

(2013) Y. Liu et al.   JOURNAL OF NEUROSCIENCE

Strength of PD-1 signaling differentially affects T-cell effector functions

(2013) F. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier

(2012) Leslie L Muldoon et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance

(2012) Xiao-Ling Chen et al.   Chinese Journal of Cancer

Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway

(2011) Jiao Chen et al.   IMMUNOBIOLOGY

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

(2010) Robert M. Prins et al.   CLINICAL CANCER RESEARCH

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

(2009) Mary Lou Affronti et al.   CANCER

Honokiol-mediated Inhibition of PI3K/mTOR Pathway

(2009) Courtney Crane et al.   JOURNAL OF IMMUNOTHERAPY

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA